UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro

Drug metabolism and disposition, 2005-06, Vol.33 (6), p.764-770

2005

Volltextzugriff (PDF)

Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384

Clinical infectious diseases, 2009-02, Vol.48 (3), p.350-361

2009

Volltextzugriff (PDF)

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211

The Journal of infectious diseases, 2007-07, Vol.196 (2), p.304-312

2007

Volltextzugriff (PDF)

Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy

AIDS patient care and STDs, 2011-03, Vol.25 (3), p.153-161

2011

Volltextzugriff (PDF)

Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIV

Journal of acquired immune deficiency syndromes (1999), 2010-03, Vol.53 (3), p.338-347

2010

Volltextzugriff (PDF)

The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV

AIDS patient care and STDs, 2008-04, Vol.22 (4), p.313-321

2008

Volltextzugriff (PDF)

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

The New England journal of medicine, 2003-05, Vol.348 (22), p.2175-2185

2003

Volltextzugriff (PDF)

Enfuvirtide, a New Fusion Inhibitor for Therapy of Human Immunodeficiency Virus Infection

Pharmacotherapy, 2004-02, Vol.24 (2), p.198-211

2004

Volltextzugriff (PDF)

CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection

Blood, 2001-07, Vol.98 (1), p.156-164

2001

Volltextzugriff (PDF)

Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients

Journal of acquired immune deficiency syndromes (1999), 2010-08, Vol.54 (5), p.470-476

2010

Volltextzugriff (PDF)

Acceptance of interferon-gamma release assay by a high-risk urban cohort

The international journal of tuberculosis and lung disease, 2011-10, Vol.15 (10), p.1334-1339

2011

Volltextzugriff (PDF)

Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication

AIDS (London), 1995-10, Vol.9 (10), p.1137-1144

1995

Volltextzugriff (PDF)

Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men

American journal of physiology: endocrinology and metabolism, 2002-07, Vol.283 (1), p.E138-E145

2002

Volltextzugriff (PDF)

Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection

AIDS patient care and STDs, 2011-03, Vol.25 (3), p.135-141

2011

Volltextzugriff (PDF)

Lymphoma Diagnosis and Plasma Epstein-Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211

Clinical infectious diseases, 2009-03, Vol.48 (5), p.642-649

2009

Volltextzugriff (PDF)

Effective HIV Case Identification Through Routine HIV Screening at Urgent Care Centers in Massachusetts

American journal of public health (1971), 2005-01, Vol.95 (1), p.71-73

2005

Volltextzugriff (PDF)

HIV Therapy — What Do We Know, and When Do We Know It?

The New England journal of medicine, 2003-12, Vol.349 (24), p.2351-2352

Skolnik, Paul R

2003

Volltextzugriff (PDF)

The effect of protease inhibitors on weight and body composition in HIV-infected patients

AIDS (London), 1998-09, Vol.12 (13), p.1645-1651

1998

Volltextzugriff (PDF)

Patient Risks, Outcomes, and Costs of Voluntary HIV Testing at Five Testing Sites Within a Medical Center

Public health reports (1974), 2008-09, Vol.123 (5), p.608-617

2008

Volltextzugriff (PDF)

Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy

AIDS (London), 1999-07, Vol.13 (11), p.1351-1357

1999

Volltextzugriff (PDF)

Evaluation of the centers for disease control and prevention's recommendations regarding routine testing for human immunodeficiency virus by an inpatient service : Who are we missing?

Mayo Clinic proceedings, 2006-04, Vol.81 (4), p.452-458

2006

Volltextzugriff (PDF)

Highly Active Antiretroviral Therapy and Viral Response in HIV Type 2 Infection

Clinical infectious diseases, 2004-06, Vol.38 (12), p.1771-1779

2004

Volltextzugriff (PDF)

Stimulation of Peroxisome Proliferator-Activated Receptors α and γ Blocks HIV-1 Replication and TNFα Production in Acutely Infected Primary Blood Cells, Chronically Infected U1 Cells, and Alveolar Macrophages From HIV-Infected Subjects

Journal of acquired immune deficiency syndromes (1999), 2002-09, Vol.31 (1), p.1-10

2002

Volltextzugriff (PDF)

Approaching the CDC's guidelines on the HIV testing of inpatients: physician-referral versus nonreferral-based testing

AIDS patient care and STDs, 2006-05, Vol.20 (5), p.311-317

2006

Volltextzugriff (PDF)

Discordant Human Immunodeficiency Virus Type 1 Drug Resistance Mutations, Including K103N, Observed in Cerebrospinal Fluid and Plasma

Clinical infectious diseases, 2002-07, Vol.35 (1), p.82-83

2002

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(64)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

Humans
(56)
Science & Technology
(56)
Life Sciences & Biomedicine
(55)
Infectious Diseases
(38)
Biological And Medical Sciences
(35)
Male
(34)
Adult
(33)
Aids/hiv
(33)
Medical Sciences
(32)
Female
(28)
Immunology
(27)
Middle Aged
(23)
Hiv
(22)
Human Immunodeficiency Virus
(21)
Virology
(19)
Human Viral Diseases
(16)
Viral Diseases
(16)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(15)
Hiv Infections - Drug Therapy
(14)
Aids
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro

Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211

Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy

Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIV

The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

Enfuvirtide, a New Fusion Inhibitor for Therapy of Human Immunodeficiency Virus Infection

CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection

Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients

Acceptance of interferon-gamma release assay by a high-risk urban cohort

Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication

Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men

Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection

Lymphoma Diagnosis and Plasma Epstein-Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211

Effective HIV Case Identification Through Routine HIV Screening at Urgent Care Centers in Massachusetts

HIV Therapy — What Do We Know, and When Do We Know It?

The effect of protease inhibitors on weight and body composition in HIV-infected patients

Patient Risks, Outcomes, and Costs of Voluntary HIV Testing at Five Testing Sites Within a Medical Center

Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy

Evaluation of the centers for disease control and prevention's recommendations regarding routine testing for human immunodeficiency virus by an inpatient service : Who are we missing?

Highly Active Antiretroviral Therapy and Viral Response in HIV Type 2 Infection

Stimulation of Peroxisome Proliferator-Activated Receptors α and γ Blocks HIV-1 Replication and TNFα Production in Acutely Infected Primary Blood Cells, Chronically Infected U1 Cells, and Alveolar Macrophages From HIV-Infected Subjects

Approaching the CDC's guidelines on the HIV testing of inpatients: physician-referral versus nonreferral-based testing

Discordant Human Immunodeficiency Virus Type 1 Drug Resistance Mutations, Including K103N, Observed in Cerebrospinal Fluid and Plasma

Suchergebnisse filtern